Publications by authors named "Jorge E Cortes"

100Publications

Pregnancy outcomes in patients treated with bosutinib.

Int J Hematol Oncol 2020 May 29;9(2):IJH26. Epub 2020 May 29.

Clinic for Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Universitätsklinikum RWTH Aachen, Aachen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh-2020-0004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510513PMC
May 2020

Financial distress among breast cancer survivors.

Curr Cancer Rep 2020 3;2(1):48-53. Epub 2020 Aug 3.

Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.25082/CCR.2020.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518546PMC
August 2020

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.

Cancer Chemother Pharmacol 2020 Oct 3;86(4):451-459. Epub 2020 Sep 3.

Clinical Pharmacology, Global Product Development, Pfizer Inc, 10555 Science Center Dr, San Diego, CA, 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-020-04132-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515941PMC
October 2020

Treatment-free remission in chronic myeloid leukemia.

Clin Adv Hematol Oncol 2019 Dec;17(12):686-696

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
December 2019

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.

N Engl J Med 2019 10;381(18):1728-1740

From the Abramson Cancer Center, University of Pennsylvania (A.E.P.), and Thomas Jefferson University (M.K.) - both in Philadelphia; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola (G.M.), L. and A. Seràgnoli Institute of Hematology, Bologna University Medical School, Bologna (S.P.), Ospedali Riuniti Villa Sofia-Cervello, Palermo (F.F.), and IRCCS San Raffaele Scientific Institute, Milan (F.C.) - all in Italy; University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Universitätsklinikum Giessen und Marburg, Marburg, Germany (A.N.); Memorial Sloan Kettering Cancer Center, New York (E. Berman); Hospital Universitari i Politècnic La Fe, Valencia, and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto Carlos III, Madrid - both in Spain (P.M.); University of Maryland Greenebaum Comprehensive Cancer Center (M.R.B.) and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (M.J.L.) - both in Baltimore; University of Chicago, Chicago (R.A.L.), and Astellas Pharma, Northbrook (C.L., N. Hasabou, X.L., E. Bahceci) - both in Illinois; University of Minnesota, Minneapolis (C.U.); University of Alabama at Birmingham, Birmingham (H.P.E., A.D.S.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.S.); University of California, San Francisco, San Francisco (R.O.); National Taiwan University, Taipei City, Taiwan (W.-C.C.); Yale University School of Medicine, New Haven, CT (N.P.); Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France (C.R.); Sendai Medical Center, National Hospital Organization, Sendai (H.Y.), and University of Fukui, Fukui (N. Hosono) - both in Japan; Seoul National University (S.-S.Y.) and Asan Medical Center, University of Ulsan College of Medicine (J.-H.L.) - both in Seoul, South Korea; Wake Forest Baptist Medical Center, Winston-Salem, NC (T.P.); and Massachusetts General Hospital, Harvard Medical School, Boston (A.T.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902688DOI Listing
October 2019

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.

Am J Hematol 2019 10 28;94(10):E256-E259. Epub 2019 Jul 28.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25571DOI Listing
October 2019

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2019 08 13;19(8):509-515.e1. Epub 2019 May 13.

City of Hope National Medical Center, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.05.008DOI Listing
August 2019

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Lancet Haematol 2019 Aug 14;6(8):e398-e408. Epub 2019 Jun 14.

Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30087-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658341PMC
August 2019

Hedgehog signaling inhibitors in solid and hematological cancers.

Cancer Treat Rev 2019 Jun 6;76:41-50. Epub 2019 May 6.

Ameriderm Research, 725 W Granada Blvd Ste 44, Ormond Beach, FL 32174, USA; University of Central Florida, Orlando, FL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.04.005DOI Listing
June 2019

A second-generation TKI should always be used as initial therapy for CML.

Authors:
Jorge E Cortes

Blood Adv 2018 12;2(24):3653-3655

Department of Leukemia, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018018655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306878PMC
December 2018

Acute myeloid leukaemia.

Lancet 2018 08 2;392(10147):593-606. Epub 2018 Aug 2.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)31041-9DOI Listing
August 2018

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

J Clin Oncol 2018 09 19;36(26):2684-2692. Epub 2018 Jul 19.

Jeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geoffrey L. Uy, Washington University School of Medicine, St Louis, MO; Jorge E. Cortes, The University of Texas MD Anderson Cancer Center, Houston, TX; Laura F. Newell, Oregon Health & Science University, Portland, OR; Tara L. Lin, University of Kansas Medical Center, Kansas City, KS; Ellen K. Ritchie, Weill Cornell Medical College, New York; Jonathan E. Kolitz, Northwell Health System, Lake Success; Daniel H. Ryan, University of Rochester, Rochester, NY; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; Stephen A. Strickland, Vanderbilt-Ingram Cancer Center, Nashville, TN; Donna Hogge, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada; Scott R. Solomon, The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA; Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA; Dale L. Bixby, University of Michigan, Grass Lake, MI; Gary J. Schiller, University of California-Los Angeles, Los Angeles; Matthew J. Wieduwilt, University of California-San Diego, La Jolla; Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Jazz Pharmaceuticals, Palo Alto; Bruno C. Medeiros, Stanford University School of Medicine, Stanford, CA; and Antje Hoering, Cancer Research and Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025PMC
September 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

J Clin Oncol 2018 06 27;36(18):1788-1797. Epub 2018 Apr 27.

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD Anderson Cancer Center, Houston, TX; Kiyomi Morita, The University of Tokyo, Tokyo; and Koichi Takahashi, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008108PMC
June 2018

Therapy-related myelofibrosis does not appear to exist.

Blood Adv 2017 Jun 26;1(14):863-866. Epub 2017 May 26.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017007369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737601PMC
June 2017

Reply to K.R. Hoffman.

J Clin Oncol 2017 02 14;35(5):567-568. Epub 2016 Nov 14.

Jorge E. Cortes, MD Anderson Cancer Center, Houston, TX; and Andreas Hochhaus, Universitätsklinikum Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2944DOI Listing
February 2017

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Am J Hematol 2018 02 4;93(2):213-221. Epub 2017 Dec 4.

Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586071PMC
February 2018

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

J Clin Oncol 2018 01 1;36(3):231-237. Epub 2017 Nov 1.

Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore, Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, London, United Kingdom; Philipp le Coutre, Charité-Universitätsmedizin Berlin, Berlin; Andreas Hochhaus, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena; Tim H. Brümmendorf, Universitätsklinikum RWTH Aachen, Aachen, Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; Eric Leip, Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966023PMC
January 2018

Treatment of Relapsed/Refractory Acute Myeloid Leukemia.

Curr Treat Options Oncol 2017 03;18(3):17

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, FC4.3062, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-017-0456-2DOI Listing
March 2017

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.

Clin Lymphoma Myeloma Leuk 2017 02 17;17(2):78-82. Epub 2016 Sep 17.

Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.09.012DOI Listing
February 2017

Mutations in AML: prognostic and therapeutic implications.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):348-355

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142505PMC
December 2016